Kura Oncology (NASDAQ:KURA) Shares Gap Down – Should You Sell?

Shares of Kura Oncology, Inc. (NASDAQ:KURA) gapped down prior to trading on Thursday . The stock had previously closed at $9.05, but opened at $8.15. Kura Oncology shares last traded at $7.77, with a volume of 1,473,412 shares traded.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Finally, Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the company from $26.00 to $19.00 in a research report on Monday, October 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market cap of $642.14 million, a PE ratio of -3.52 and a beta of 0.78. The stock has a 50 day simple moving average of $8.83 and a two-hundred day simple moving average of $15.16.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter last year, the company posted ($0.50) earnings per share. Sell-side analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,255 shares of company stock valued at $100,739. 5.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC boosted its position in Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after acquiring an additional 583,155 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after purchasing an additional 41,535 shares during the last quarter. Franklin Resources Inc. grew its holdings in Kura Oncology by 1.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock valued at $28,687,000 after buying an additional 23,113 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Kura Oncology by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 635,494 shares of the company’s stock worth $5,535,000 after acquiring an additional 10,542 shares during the last quarter. Finally, Alethea Capital Management LLC raised its holdings in shares of Kura Oncology by 108.2% during the 3rd quarter. Alethea Capital Management LLC now owns 553,542 shares of the company’s stock worth $10,816,000 after acquiring an additional 287,636 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.